BioEquity Watch
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines.
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 61 | Founded | a year ago | Last Issue | 10 days ago |
| Active | |||||
Read this Newsletter
bioequitywatch.substack.comLatest Issues
Ultragenyx: A $RARE Short?
Rating: BEARISH | Target Price: $16.00 | Current Price: $25.67 | Implied Change: -37.67%
AUTHOR’S TAKE
The market treats Ultragenyx like a diversified, safe-haven rare disease leader on the cusp of blockbuster commercial expansi...
Can Inventiva crack the crowded MASH market? ($IVA)
Rating: BULLISH | Target Price: $7.50 | Current Price: $4.62 | Implied Change: +62.3%
AUTHOR’S TAKE
Inventiva S.A. is a high-conviction, binary biotech setup with a lot of upside. The market is pricing this stock like a failure...
Outpatient Disruptor or Micro-Cap Gamble? : The Asymmetric Case for Immix Biopharma ($IMMX)
Rating: BULLISH | Target Price: $21.20 | Current Price: $8.95 | Implied Change: +136.87%
AUTHOR’S TAKE
The market is mispricing Immix Biopharma because it’s treating NXC-201 like a just another toxic, hard to administer CAR T. H...
If you don't change anything, nothing changes : A look at $UNCY.
Rating: BEARISH | Target Price: $1.20 | Current Price: $5.00 | Implied Change: -76%
AUTHOR’S TAKE
We are bearish on Unicycive Therapeutics with a $1.20 price target, a 76% drop from its current $5.00 trading level. Investors are...
Can we reach the Summit? ($SMMT)
Rating: BEARISH | Target Price: $5.90 | Current Price: $15.52 | Implied Change: -62%
AUTHOR’S TAKE
The market is way too optimistic on Summit Therapeutics right now, pushing its valuation to an unsustainable $12 billion based en...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for BioEquity Watch.
| Subscribers | Engagement | 74 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines.
Frequently Asked Questions
How can I access the email archive for BioEquity Watch?
You can find recent issues that have been published by BioEquity Watch on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does BioEquity Watch have?
To see how many people subscribe to BioEquity Watch, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in BioEquity Watch?
Newsletter advertising can be extremely effective when it's done right. Before you pitch BioEquity Watch as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like BioEquity Watch?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact BioEquity Watch using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to BioEquity Watch?
Scroll up to where it says Related Newsletters to see other publications like BioEquity Watch. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact BioEquity Watch?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.